FDA approves CSL Behring rare disease treatment

The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy developed by CSL Behring. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. The condition, which afflicts an estimated 40,000 people in the United States, can cause nerve numbness or tingling, muscle weakness, fa tigue and other symptoms. An…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news